Romiplostim Treatment for Thrombocytopenia in Patients With Wiskott-Aldrich Syndrome.

Wiskott-Aldrich Syndrome Clinical Trial

Official title:

Retrospective Chart Review of Children With Wiskott-Aldrich Syndrome Who Received Romiplostim in Treatment of Thrombocytopenia.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04350164
• Other study ID #: NCPHOI-2020-02
• Status: Completed
• Start date: April 1, 2012
• Est. completion date: June 2020

Study information

• Verified date: December 2020
• Source: Federal Research Institute of Pediatric Hematology, Oncology and Immunology
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The rationale for this retrospective study is to evaluate the efficacy and safety of thrombopoietin-receptor agonist (TPO-RA) romiplostim for reducing thrombocytopenia and bleeding tendency in pediatric participants with genetically confirmed Wiskott-Aldrich syndrome (WAS).

Description:

Thrombocytopenia is a life-threatening symptom in WAS patients. Subjects with WAS are at increased risk of debilitating and\ or life-threatening bleedings due to low platelet numbers. Hematopoietic stem cell transplantation is an effective treatment of WAS and all its symptoms yet requires time for donor search and is not widely utilized in cases with mild WAS with isolated thrombocytopenia. TPO-RAs have been used in individual WAS patients, wherein publications describing large WAS cohorts treated with TPO-RAs are lacking. Based on the previous reports, WAS patients in our Center have been receiving treatment with TPO-RA romiplostim since 2012. The aim of the study is to retrospective analyze patients' data in order to asses treatment efficacy and safety of romiplostim in WAS thrombocytopenia. The study will collect and analyze information that is already in the patients' medical records. Information about clinical data (assessment of bleeding tendency with a modified World Health Organization (WHO) Bleeding Scale), laboratory values (such as clinical and biochemical analysis of blood) will be included. Evaluation of the efficacy therapy was based on the results of physical examination, including bleeding events at the time of diagnosis and after 6-month TPO-RA was initiated and platelet response. A complete response was defined as a platelet count >100 x 109/L in the absence of bleeding symptoms, partial - 30 x 109/L higher than the patient's pretreatment baseline count to 100 x 109/L. Non-response was defined as not achieving a platelet count of > 30 x 109/L from the baseline count.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 67
• Est. completion date: June 2020
• Est. primary completion date: December 27, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 18 Years

Eligibility

Inclusion Criteria:

• Age under < 18 years
• Subject/legal representative has signed written informed consent. ?
• Subjects diagnosed with WAS based on genetic findings.
• Subjects with thrombocytopenia (platelet count of less than 70 x 109/L).
• Subjects with a history of bleeding.
• Subjects received treatment with romiplostim 8-9 µg /kg for at least 30 days
• Available records of the points of analysis

Exclusion Criteria:

• Patients, who do not meet the inclusion criteria.

Related Conditions & MeSH terms

• Syndrome
• Thrombocytopenia
• Wiskott-Aldrich Syndrome

Intervention

Drug:
• Romiplostim
romiplostim once weekly subcutaneously at an initial dose of 8-9 µg/kg per week for at least 1 month to 1 year.

Locations

Country	Name	City	State
Russian Federation	Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology	Moscow

Sponsors (1)

Lead Sponsor	Collaborator
Federal Research Institute of Pediatric Hematology, Oncology and Immunology

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The percentage of participants with overall platelet response (complete response + partial response)	A complete response defined as a platelet count >100 x 109/L, partial - 30 x 109/L higher than the patient's pretreatment baseline count to 100 x 109/L.	1 month (30 day +/- 14 days)
Secondary	Percentage of patients with a platelet response		until discontinuation, from at least one month to one year
Secondary	Number of participants with bleeding events and severity of bleeding	The incidence and severity of bleeding events evaluated with a modified World Health Organization (WHO) Bleeding Scale.; (G1=Petechiae, epistaxis <30 min, G2=Mild blood loss, hematomas, epistaxis >30 min, melanotic stool G3=Gross blood loss, requiring blood transfusions, G4=Fatal bleeding).	until discontinuation, from at least one month to one year
Secondary	Number of participants with adverse events		until discontinuation, from at least one month to one year